

**Amendments to the Drawings**

Please delete in their entirety Figures 4, 5, 8, and 9. The attached sheets of replacement figures include replacement sheets for previous Figures 6, 7, and 10-17, now re-numbered as Figures 4, 5, and 8-13, respectively. For the avoidance of any doubt, the only changes to the attached sheets of replacement figures relative to the previous versions of the figures relate to the numbering of the figures. Also included amongst the attached sheets of replacement figures are annotated sheets (marked-up) showing Figures 4, 5, 8, and 9 deleted in their entirety. Because it is not necessary to amend or renumber previous Figures 1, 2, and 3, Applicants do not enclose replacement sheets for Figures 1, 2, or 3. The attached sheets of replacement figures are in compliance with 37 CFR 1.84 and 1.121(d).

Attachment: Replacement Sheets and Annotated (marked-up) Sheets.

**Remarks/Arguments**

This paper is filed in response to the Notice to Comply dated April 30, 2010.

In the Notice to Comply dated April 30, 2010, the Examiner asserted that the Figures 4, 5, 8, and 9 depict nucleotide and/or amino acid sequences that do not comply with the requirements of 37 CFR 1.821 through 1.825. More specifically, the Examiner alleged that the sequences depicted in Figures 4, 5, 8, and 9 “do not constitute an appropriate depiction of the *intact sequence* with the pertinent X amino acids at the CDRs.” Furthermore, the Examiner has kindly suggested to the Applicants that “[a] sequence listing for the intact sequence is required with the Xs listed as CDR1, etc, wherein X is defined per the specification.” Rather than amending the sequence listing as suggested by the Examiner, Applicants kindly request the cancellation of Figures 4, 5, 8, and 9. Accordingly, Applicants also hereby submit replacement sheets for previous Figures 6, 7, and 10-17, now re-numbered as Figures 4, 5, and 8-13, respectively. Applicants respectfully assert that cancellation of Figures 4, 5, 8, and 9 effectively removes the basis for the alleged non-compliance identified in the Notice to Comply dated April, 30, 2010. Additionally, Applicants have amended and request entry in the present application the amended Drawings provided herewith. Applicants, through the undersigned attorney, certify that the amended Drawings include no new matter.

If there are any outstanding issues regarding this response or application, the Examiner is invited to contact the undersigned attorney by telephone at (317) 651-1541 to resolve such issues, so that the claims may be allowed and issued without further delay.

Respectfully submitted,

/Robert L. Sharp/  
Attorney Name  
Attorney for Applicants  
Registration No. 45,609  
Phone: (317) 651-1541

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

June 1, 2010